Brokerages Expect BioScrip Inc (BIOS) to Post -$0.10 EPS

Wall Street brokerages forecast that BioScrip Inc (NASDAQ:BIOS) will post ($0.10) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for BioScrip’s earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.11). BioScrip reported earnings per share of ($0.11) during the same quarter last year, which suggests a positive year-over-year growth rate of 9.1%. The company is scheduled to issue its next earnings report on Tuesday, August 14th.

According to Zacks, analysts expect that BioScrip will report full-year earnings of ($0.31) per share for the current financial year, with EPS estimates ranging from ($0.32) to ($0.29). For the next financial year, analysts forecast that the company will report earnings of ($0.14) per share, with EPS estimates ranging from ($0.18) to ($0.11). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow BioScrip.

BioScrip (NASDAQ:BIOS) last issued its earnings results on Thursday, May 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The business had revenue of $168.60 million for the quarter, compared to analyst estimates of $164.72 million. The business’s revenue was down 22.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.18) earnings per share.

Several brokerages have issued reports on BIOS. BidaskClub raised shares of BioScrip from a “buy” rating to a “strong-buy” rating in a report on Thursday. Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Tuesday, May 15th. Craig Hallum reaffirmed a “buy” rating and issued a $3.50 target price on shares of BioScrip in a report on Thursday, March 8th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $3.25 target price on shares of BioScrip in a report on Thursday, March 8th. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $3.44.

Institutional investors have recently modified their holdings of the business. Gotham Asset Management LLC purchased a new position in BioScrip in the fourth quarter worth about $114,000. MetLife Investment Advisors LLC purchased a new position in shares of BioScrip during the fourth quarter valued at approximately $174,000. Two Sigma Advisers LP raised its holdings in shares of BioScrip by 100.4% during the fourth quarter. Two Sigma Advisers LP now owns 128,245 shares of the company’s stock valued at $373,000 after purchasing an additional 64,238 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of BioScrip by 34.4% during the fourth quarter. Wells Fargo & Company MN now owns 217,450 shares of the company’s stock valued at $634,000 after purchasing an additional 55,636 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. purchased a new position in shares of BioScrip during the first quarter valued at approximately $635,000. 85.46% of the stock is owned by institutional investors and hedge funds.

Shares of BioScrip stock opened at $2.93 on Wednesday. The company has a debt-to-equity ratio of -4.79, a quick ratio of 1.30 and a current ratio of 1.70. BioScrip has a 52-week low of $1.80 and a 52-week high of $3.39.

About BioScrip

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply